Welcome to our dedicated page for Imac Hldgs SEC filings (Ticker: BACK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IMAC Holdings, Inc. (BACK) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its precision oncology strategy, financing structure, and reporting status. As a public company with SEC file number 001‑38797 and CUSIP 44967K302, IMAC uses its filings to describe material agreements, debt obligations, and timing of periodic reports.
Recent Form 8‑K reports detail multiple promissory notes and a Securities Purchase Agreement for senior secured notes. These filings outline original principal amounts, purchase prices, maturities, security interests, and customary events of default, including bankruptcy or insolvency events. One 8‑K describes a Security and Pledge Agreement granting a first‑priority security interest in substantially all assets of IMAC and certain subsidiaries, including Ignite Proteomics LLC and several healthcare‑related entities, as collateral for senior secured notes.
IMAC’s filings also include a Form 12b‑25 (NT 10‑Q) explaining delays in filing its Quarterly Report on Form 10‑Q for the period ended September 30, 2025. In that notification, the company cites delays in compiling financial and other information and states its intention to file within the allowed extension period. Separate Nasdaq notices referenced in company news discuss deficiency letters and exceptions related to timely filing requirements, which are closely tied to the information in IMAC’s periodic reports.
On this SEC filings page, users can review IMAC’s 8‑Ks on new debt arrangements, security agreements, and guaranties, as well as late‑filing notifications and other disclosures. Stock Titan’s tools can surface key elements from lengthy documents—such as the scope of collateral, identities of guarantor subsidiaries, or the nature of reporting delays—helping readers understand how IMAC structures its obligations and how its regulatory reporting aligns with its evolving precision oncology business through Ignite Proteomics.
IMAC Holdings, Inc. entered into a Securities Purchase Agreement with several investment funds on December 19, 2025 to issue senior secured notes with an aggregate original principal amount of
The notes mature on
Multiple operating subsidiaries provided a joint and several guaranty of all obligations under the purchase agreement, notes, and related documents, reinforcing the lenders’ claims if the company fails to perform.
IMAC Holdings, Inc. reported that on December 26, 2025 it entered into a new short-term financing. The company issued a secured promissory note with an aggregate principal amount of $260,400 for an aggregate purchase price of $186,000, creating a new direct financial obligation.
The note matures on January 31, 2026 and may be prepaid in whole or in part at any time without penalty. It includes customary representations, warranties and covenants, and specifies events of default under which the outstanding principal can be declared immediately due and payable, including certain bankruptcy or insolvency events involving the company.
IMAC Holdings, now centered on proteomic cancer diagnostics, reported Q3 2025 net revenue of $0.02 million and a net loss of $3.1 million.
Revenue remains very small while costs are high, producing a negative gross margin and a $0.75 million impairment charge to write off lab equipment whose fair value was determined to be zero. Interest expense rose with new high-discount promissory notes, and total notes payable reached $4.4 million in principal, with $0.5 million unpaid past the November 14, 2025 maturity.
At September 30, 2025, cash was $0.05 million against a $13.0 million working capital deficit and a $13.3 million current liability balance, leading management to state substantial doubt about the company’s ability to continue as a going concern. The company faces Medicare audit overpayment disputes, including a $2.7 million reserve, carries $57.7 million in preferred stock liquidation preference, and discloses multiple material weaknesses in internal control over financial reporting.
IMAC Holdings, Inc. entered into a new secured promissory note on December 11, 2025, creating a direct financial obligation. The note has an aggregate principal amount of $247,800 for an aggregate purchase price from the lenders of $177,000, providing short-term funding on a discounted basis.
The note is secured and matures on February 13, 2026, giving the company a defined near-term repayment date while allowing it to prepay any portion of the outstanding principal at any time without penalty. It includes customary representations, warranties, covenants, and events of default, including bankruptcy or insolvency events that could cause the full principal to become immediately due and payable.
IMAC Holdings, Inc. entered into a secured promissory note with a lender, providing for aggregate principal of $245,000 in exchange for an aggregate purchase price of $175,000.
The note, issued on November 25, 2025, matures on February 13, 2026, and may be prepaid in whole or in part at any time without penalty. It includes customary representations, warranties, covenants, and events of default, including specified bankruptcy or insolvency events that could cause all outstanding principal to become immediately due and payable.
The company describes this debt arrangement as a material definitive agreement and has filed the form of the note as an exhibit by reference.
IMAC Holdings, Inc. (BACK) entered into a new short-term financing arrangement through a secured promissory note. On November 14, 2025, the company issued a Note with an aggregate principal amount of $210,000 to a lender in exchange for an aggregate purchase price of $150,000, reflecting an original issue discount. The Note is secured and matures on February 13, 2026, and IMAC may prepay any portion of the principal at any time without penalty. The Note includes customary representations, warranties, covenants and events of default, including bankruptcy or insolvency events that could cause the outstanding principal to become immediately due and payable.
IMAC Holdings, Inc. (BACK) entered into a new financing. On October 28, 2025, the company issued an unsecured promissory note with an aggregate principal amount of
The note matures on
IMAC Holdings (BACK) entered into new debt financing. On October 14, 2025, the company issued an unsecured promissory note with an aggregate principal of $201,600 for an aggregate purchase price of $144,000. The note matures on December 24, 2025, and the company may prepay any portion of principal at any time without penalty.
The agreement includes customary representations, warranties, and covenants, and specifies events of default under which the outstanding principal may be accelerated, including certain bankruptcy or insolvency events involving the company.
FAQ
What is the current stock price of Imac Hldgs (BACK)?
What is the market cap of Imac Hldgs (BACK)?
